VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of VSV-hIFNbeta-NIS in patients with
relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma.

SECONDARY OBJECTIVES:

I. To determine the safety profile of VSV-hIFNbeta-NIS. II. To estimate clinical response
rate in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell
lymphoma overall and by disease type.

III. To estimate progression-free and overall survival in patients with relapsed/refractory
multiple myeloma, acute myeloid leukemia, or T-cell lymphoma overall and by disease type.

TERTIARY OBJECTIVES:

I. To determine the time course of viral gene expression and virus elimination, and the
biodistribution of virally infected cells at various times points after infection with
VSV-hIFNbeta-NIS using planar and single photon emission computed tomography (SPECT)/computed
tomography (CT) imaging.

II. To assess virus replication, viremia, viral shedding in urine and respiratory secretions,
and virus persistence after systemic administration of VSV-hIFNbeta-NIS.

III. To characterize the pharmacodynamics (PD) of VSV-IFNbeta-NIS by way of measuring serum
interferon-beta and also vesicular stomatitis virus (VSV)-real time (RT)-polymerase chain
reaction (PCR) of VSV-IFNbeta-NIS.

IV. Assess CD8+ T cell (both general and VSV-IFNbeta-NIS specific) and natural killer (NK)
cell responses.

V. Gene expression analysis pre- and post-virotherapy. VI. Assess presence of VSV in tumor
and normal tissues subsequent to administration of intravenous (IV) VSV-IFNbeta-NIS.

OUTLINE: This is a dose escalation study.

Patients receive VSV-IFNbeta-NIS intravenously (IV) over 30 minutes on day 1, and then
undergo SPECT/CT 3-5 days later.

After completion of study treatment, patients are followed up for 28 days, and then every 3
months for up to 1 year.

Inclusion Criteria:

- Relapsed or refractory:

- Multiple myeloma (MM) previously treated with an immunomodulatory drug (IMID), a
proteosome inhibitor and an alkylating agent; OR

- Oligoblastic acute myeloid leukemia (AML) (=< 30% blasts), excluding acute
promyelocytic leukemia (PML-RARA rearranged- AML-M3); either primary refractory
or relapsed/refractory disease after at least two front line chemotherapy
regimens (note: induction and consolidation chemotherapy is considered one line
of therapy, additionally allogeneic stem cell transplant after induction/
consolidation is not considered an additional line of therapy); diagnosis based
on 2008 World Health Organization (WHO) criteria; OR

- Relapsed T-cell lymphoma (TCL) or the following types: peripheral T-cell
lymphoma-NOS (PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL), anaplastic
large cell (ALCL), and cutaneous TCL (CTCL) of mycosis fungoides (MF); patients
should have failed standard therapy and in the case of PTCL-NOS, AITL, and ALCL
either have failed or be ineligible for high-dose therapy with autologous stem
cell transplant

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 times upper
limit of normal (ULN)

- Creatinine =< 2.0 mg/dL

- Direct bilirubin =< 1.5 x ULN

- International normalized ratio (INR)/prothrombin time (PT) and activated partial
thromboplastin time (aPTT) =< 1.5 x ULN

- If baseline liver disease, Child Pugh score not exceeding class A

- Negative pregnancy test for persons of child-bearing potential

- FOR MULTIPLE MYELOMA ONLY: Measurable disease of multiple myeloma as defined by at
least ONE of the following:

- Serum monoclonal protein >= 1.0 g/dL by protein electrophoresis

- >= 200 mg of monoclonal protein in the urine on 24-hour electrophoresis

- Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum
immunoglobulin kappa to lambda free light chain ratio

- FOR MULTIPLE MYELOMA ONLY: Absolute neutrophil count (ANC) >= 1000/uL

- FOR MULTIPLE MYELOMA ONLY: Platelet (PLT) >= 100,000/uL

- FOR MULTIPLE MYELOMA ONLY: Hemoglobin >= 8.5 g/dl

- FOR AML ONLY: No ANC restriction

- FOR AML ONLY: PLT >= 10,000/uL (transfusion to get platelets >= 10,000 is allowed)

- FOR AML ONLY: Hemoglobin >= 7.5 g/dl

- FOR AML ONLY: Absence of uncompensated disseminated intravascular coagulation (DIC- as
diagnosed by standard International Society on Thrombosis and Hemostasis [ISTH]
criteria)

- FOR TCL ONLY: ANC >= 1,000/uL

- FOR TCL ONLY: PLT >= 100,000/uL

- FOR TCL ONLY: Hemoglobin >= 8.5 g/dl

- FOR TCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have
at least one lesion that has a single diameter of > 2 cm or tumor cells in the blood >
5 x10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at least one
diameter and photographed with a ruler and the images are available in the medical
record

- Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollment
lumbar puncture not mandatory

- Ability to provide written informed consent

- Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up

- Life expectancy >= 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

- Willing to provide mandatory biological specimens for research purposes

Exclusion Criteria:

- Availability of and patient acceptance of curative therapy

- Uncontrolled infection

- Active tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitis

- Any of the following prior therapies:

- Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =< 2 weeks prior
to registration

- Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration

- Experimental agent in case of AML or TCL within 4 half-lives of the last dose of
the agent

- New York Heart Association classification III or IV, known symptomatic coronary artery
disease, or symptoms of coronary artery disease on systems review, or known cardiac
arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])

- Active CNS disorder or seizure disorder or known CNS disease or neurologic
symptomatology; in case of AML active CNS involvement as detected by lumbar puncture
or neuro-imaging (only to be done if clinically indicated)

- Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or
immunosuppression

- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
considered investigational (used for a non-Food and Drug Administration [FDA] approved
indication and in the context of a research investigation);

- NOTE: in AML, the concurrent use of hydroxyurea to help control proliferative
counts is allowed throughout the treatment protocol;

- NOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid
soaks, etc. to control pruritis and prevent infection; no topical chemotherapy is
allowed (no topical nitrogen mustard)

- Any of the following because this study involves an investigational agent whose
genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are
unknown:

- Pregnant women or women of reproductive ability who are unwilling to use
effective contraception

- Nursing women

- Men who are unwilling to use a condom (even if they have undergone a prior
vasectomy) while having intercourse with any woman, while taking the drug and for
4 weeks after stopping treatment

- Acute promyelocytic leukemia (AML - M3)

- Prior allogeneic bone marrow transplant

- Multiple myeloma only: >= 15% plasmas cells or plasmacytoma > 5 cm in largest diameter

- TCL only: Any mass >= 5 cm

- AML only: current disseminated intravascular coagulopathy (DIC)